A 52-week, Multicenter, Open-label Study to Evaluate the Effectiveness of an Intramuscular Depot Formulation of Aripiprazole (OPC-14597) as Maintenance Treatment in Patients With Bipolar I Disorder
Phase of Trial: Phase III
Latest Information Update: 09 Oct 2018
Price : $35 *
At a glance
- Drugs Aripiprazole (Primary)
- Indications Bipolar I disorders
- Focus Adverse reactions; Registrational
- Acronyms ATLAS
- Sponsors Otsuka Pharmaceutical Development & Commercialization
- 09 Oct 2018 Results assessing functional recovery and symptomatic remission after maintenance treatment with aripiprazole once-monthly in patients with bipolar I disorder, presented at the 31st Annual Congress of the European College of Neuropsychopharmacology
- 04 May 2017 Status changed from recruiting to completed.
- 08 Oct 2015 Planned number of patients changed from 1000 to 755 as reported by ClinicalTrials.gov record.